Attovia Therapeutics, Inc. (ATTO)
13.83
-0.67
(-4.62%)
USD |
NASDAQ |
Oct 23, 16:00
13.83
0.00 (0.00%)
After-Hours: 20:00
Attovia Therapeutics Net Income (Quarterly) : -20.69M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.69M |
| March 31, 2026 | -18.66M |
| Date | Value |
|---|---|
| June 30, 2025 | -14.44M |
| March 31, 2025 | -15.42M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.45M |
| Total Expenses (Quarterly) | 21.14M |
| EPS Diluted (Quarterly) | -0.4532 |
| Enterprise Value | 778.78M |
| Gross Profit Margin (Quarterly) | 45.33% |
| Profit Margin (Quarterly) | -4.60K% |
| Earnings Yield | -10.96% |
| Normalized Earnings Yield | -10.94 |